Swiss guidelines for counselling and testing

Genetic predisposition to breast and ovarian cancer


* Division of Oncology and Division of Genetic Medicine, University Hospitals of Geneva, CH-1205 Geneva; a Tumor- und Brustzentrum ZeTuP, CH-9006 St. Gallen; b Division of Gynecologic Oncology, University Hospital Basel, CH-4055 Basel; c Sonnenhof Klinik Engeried, CH-3012 Bern; d Division of Medical Genetics, University Hospital Basel, CH-4031 Basel; e Division of Oncology, Hôpital du Jura-Delémont, CH-2800 Delémont; f Tumorzentrum ZeTuP, Rapperswil-Jona, CH-8640 Rapperswil; g Istituto Oncologico della Svizzera Italiana, Ospedale Regionale Bellinzona e Valli, CH-6500 Bellinzona; h Division of Oncology, Hôpital de Morges, CH-1110 Morges; i Division of Medical Oncology, UCI University Cancer Center Inselspital, CH-3010 Bern; j Division of Medical Genetics, CHUV-Lausanne University Hospital, CH-1011 Lausanne

*these authors contributed equally to this publication

These guidelines have been approved by the SAKK Breast Cancer Project Group and the Gynecological Cancers Working Group. This document reflects clinical and scientific advances as of the date of publication and is subject to change.

Résumé

Ces recommandations ont été élaborées à l’attention des médecins praticiens afin de mieux définir les personnes concernées par une démarche clinique particulière dans le contexte d’antécédents médicaux personnels ou familiaux évocateurs de prédispositions génétiques au cancer du sein et de l’ovaire. Cette démarche comprend une évaluation oncogénétique, soit un conseil génétique dédié pouvant aboutir à la proposition d’analyses moléculaires. Ces dernières visent à identifier des variants pathogéniques constitutionnels dans des gènes responsables d’un risque notablement accru de développer des cancers du sein et de l’ovaire par rapport à la population générale. Des mesures particulières de surveillance et de prévention dont l’efficacité est démontrée sont alors disponibles pour les personnes portant de telles prédispositions génétiques.

Ces recommandations concernent également les représentants de l’assurance obligatoire des soins selon la loi fédérale sur l’assurance-maladie (LAMal) pour la prise en charge des coûts de ces analyses moléculaires conformément à la législation en vigueur. Par ailleurs, ces directives sont très similaires à celles déjà émises dans d’autres pays ou par d’autres sociétés savantes internationales.


Introduction

BRCA1 and BRCA2 are the main genes involved in the hereditary breast and ovarian cancer syndrome with an autosomal dominant mode of inheritance. The frequency of germ-line BRCA1/BRCA2 pathogenic variants is about 1:400 to 1:800 among healthy women from the Western non-Jewish white population. Carrying a germ-line mutation in BRCA1 or BRCA2 is associated with 40% to 75% cumulative risk of developing breast cancer and 15% to 60% cumulative risk for ovarian cancer by age 70 years [1]. About 3–5% of all breast cancer and 10–15% of unselected invasive ovarian cancer cases are BRCA-related [2]. Other rare high- to moderate-risk inherited syndromes can associate breast or ovarian cancer [3, 4].

The rapid translation of next-generation or massively parallel sequencing technology in diagnostic laboratory has opened impressive perspectives by allowing to test for multiple genes in a single assay (gene panel or exome) with substantial reductions both in costs and turn-around time. Some important issues have also been raised by this technological revolution, e.g. clinical validity or clinical utility of several genetic results, or identification of multiple variants of uncertain clinical significance [5, 6].

In Switzerland, testing for genetic predisposition to hereditary breast/ovarian cancer, particularly BRCA1/BRCA2, is available in a clinical setting. Cancer risk assessment and genetic counselling are mandatory before and after genetic testing (i.e. pre- and post-test...
Swiss guidelines for referral individuals for risk assessment, genetic counselling and testing for breast/ovarian cancer predisposition syndrome

I. Individuals with a close relative with a known pathogenic variant in **BRCA1** or **BRCA2**, or in another gene conferring high risk for breast and ovarian cancer.

II. WOMEN with a personal history of BREAST CANCER and one of the following:
   - Age at diagnosis <40 years;
   - Triple negative (oestrogen receptor, progesterone receptor and HER2 negative) breast cancer ≤60 years;
   - Age at diagnosis ≤50 years, with ≥2 close relatives with breast cancer at any age or with only 1 close relative with breast cancer ≤50 years;
   - Bilateral breast cancer, if the first cancer was diagnosed ≤50 years;
   - Bilateral breast cancer at any age, with ≥1 close relative with breast cancer (if only one relative affected, then age at diagnosis ≤50 years);
   - Diagnosed at any age, with ≥1 close relative with ovarian cancer at any age;
   - Diagnosed at any age, with ≥2 close relatives with breast cancer (particularly if ≥1 breast cancer diagnosed ≤50 years or if bilateral breast cancer);
   - A close male relative with breast cancer (any age);
   - A personal history of ovarian cancer;

III. Women with a personal history of OVARIAN cancer and one of the following:
   - Non-mucinous epithelial subtypes, particularly high grade serous histology, at any age;
   - A personal history of breast cancer;
   - One or more close relatives with ovarian cancer (any age);
   - One or more close female or male relatives with breast cancer, particularly if breast cancer diagnosed ≤50 years;

IV. MEN with a personal history of BREAST CANCER:
   - Particularly, if one or more close male relatives with breast cancer;
   - Particularly, if one or more close female relatives with breast or ovarian cancer;

V. Ashkenazi Jewish heritage:
   Search for the 3 founder **BRCA1** and **BRCA2** pathogenic variants regardless of personal or family history;

VI. Family history only (i.e. unaffected individuals):
   One or more close relatives with breast or ovarian cancer fulfilling one of the above criteria (points II–IV).

---

1. Close relative is defined as a first- or a second-degree relative on the same side of the family;
   - first-degree relatives: mother/father, sister/brother, daughter/son;
   - second-degree relatives: grandparents, aunt/uncle, niece/nephew, grandchildren.
2. Ovarian cancer also includes primary peritoneal cancer and fallopian tube cancer.
3. **BRCA1**: c.68_69delAG, c.5266dupC; **BRCA2**: c.5946delT.

---

Swiss guidelines for genetic counselling and testing for breast and ovarian cancer predisposition

The present paper summarises the Swiss guidelines for genetic counselling and ultimately testing individuals with an increased probability for carrying mutations in high-risk breast/ovarian cancer predisposition genes, particularly **BRCA1**/**BRCA2**. Risk assessment is mainly based on some particular personal and/or family history patterns on both side of the family, including:

- early-age onset of breast cancer;
- number of breast cancer cases across generations;
- bilateral breast cancer;
- ovarian cancer: of note, peritoneal and fallopian tube cancers should be considered as part of the spectrum of the hereditary breast/ovarian cancer syndrome;
- ethnic origin: currently limited to Ashkenazi Jews in our population.

Adapted from recently published guidelines [3, 4, 8, 10], it is reasonable to refer individuals with the following personal and/or family history for genetic counselling and testing for high-risk predisposition genes, particularly **BRCA1**/**BRCA2** (see box on the left).

Comments

1) Meeting one or more of these criteria warrants further personalised genetic risk assessment and genetic counselling which will cover explanation of inheritance pattern, available testing options, discussion of disease management, treatment, surveillance and prevention options.
2) Consider referral of cases with a weaker history of breast cancer if there is a family history of pancreatic cancer or prostate cancer, particularly at an early age at diagnosis (<60 years), or sarcoma (<45 years), or glioma, or childhood adrenal cortical carcinoma, or complicated patterns of multiple cancers at a young age.

3) Particular clinical situations not included in one of the above criteria should be discussed individually, e.g. ductal carcinoma in situ (DCIS) at an early age of onset (<40 years), small or uninformative families or adoption.

4) Borderline ovarian tumour is not considered as part of the spectrum of the hereditary breast/ovarian cancer syndrome.

5) Among the Ashkenazi Jewish population, the 3 BRCA1 and BRCA2 founder pathogenic variants (BRCA1: c.68_69delAG, c.5266dupC; BRCA2: c.5946delT) account for 98–99% of mutations identified and are carried by about 2.6% (1/40) of this population.

6) When an appropriate affected family member is unavailable, testing of a family relative without a cancer diagnosis should be considered.

7) Genetic testing for adult-onset diseases, such as BRCA1/BRCA2-related disorders, is not recommended in children <18 years.

8) Genetic testing on formalin-fixed and paraffin-embedded tumoral tissue is yet feasible to identify mutations predictive of response to treatment, e.g. identification of somatic or potentially germ-line BRCA1 or BRCA2 pathogenic variants and decision to introduce platinum-based drugs or poly(ADP-ribose) polymerase inhibitors. Currently, this molecular approach does not replace the search for germ-line pathogenic variants based on a blood sample in the context of a suspicion of genetic predisposition to hereditary breast/ovarian cancer.

Conclusion

Cancer genetic predisposition is a complex clinical and socio-psychological condition which requires harmonisation in medical practice and close interdisciplinary collaboration. An adequate identification of individuals who can potentially benefit from genetic counselling and testing is the essential prerequisite for a positive risk/benefit ratio. Health care professionals should therefore be aware of the personal and/or family history patterns that are associated with an increased risk for germ-line pathogenic variants to allow for the most effective management of hereditary breast and ovarian cancer families and the most efficient utilisation of health care resources.

Acknowledgements

We thank all the members of the SAKK Section Network for Cancer Predisposition Testing and Counseling and other colleagues for their fruitful comments.

Disclosure statement

No financial support and no other potential conflict of interest relevant to this article was reported.

References


